- Home
- GALT vs SGMT Comparison
GALT vs SGMT Comparison
Compare GALT & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GALT | SGMT |
|---|---|---|
| Founded | 2000 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 176.7M | 164.6M |
| IPO Year | 2008 | 2021 |
Fundamental Metrics
Financial Performance| Metric | GALT | SGMT |
|---|---|---|
| Price | $3.16 | $5.34 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 9 |
| Target Price | $8.50 | ★ $27.00 |
| AVG Volume (30 Days) | 281.7K | ★ 374.1K |
| Earning Date | 01-01-0001 | 06-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.15 | $1.73 |
| 52 Week High | $7.13 | $11.41 |
Technical Indicators
Market Signals| Indicator | GALT | SGMT |
|---|---|---|
| Relative Strength Index (RSI) | 50.65 | 44.40 |
| Support Level | $2.88 | $4.97 |
| Resistance Level | $3.27 | $6.49 |
| Average True Range (ATR) | 0.24 | 0.34 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 44.27 | 20.35 |
Price Performance
Historical ComparisonAbout GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
About SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.